Abstract. An Anticoagulation Clinic Service (ACS) has been proposed as one strategy for improving warfarin treatment for patients with atrial fibrillation. In the Managing Anticoagulation Services Trial (MAST), ACSs meeting specifications for high quality care were established in six managed care organizations (MCOs) which had the patients and resources to support this initiative. The trial followed 1165 patients age ≥65 years who had atrial fibrillation as the primary reason for anticoagulation and were enrolled in a participating MCO. The 593 patients in the intervention group saw physicians in a practice cluster which had randomly been assigned to have access to an ACS. These physicians used the ACS on average for about 48% of eligible patients. The 572 patients in the control group received care from physicians in a practice cluster which could not refer patients to the ACS established for the trial but was otherwise unrestricted. The two clusters were compared on the proportion of time warfarin-treated patients were in the target range (2-3) prothrombin time-international normalized ratio (INR) during a 9-month baseline and a 9-month follow-up period. Among patients (n = 264) for whom data were available for both periods, the changes in percentages of time in the target range were similar in the intervention cluster (baseline: 47.7%; follow-up 55.6%) and in the control cluster (baseline: 49.1%; followup: 52.3%; intervention effect: 5%; 95% confidence interval: −5% to 14%; P = 0.32). In both practice clusters, patients had subtherapeutic INR values (1.5 to 1.99) about one fourth of the time. Providing an ACS in a managed care setting did not appear to improve anticoagulation care over the usual care provided at the sites in this trial but could be a reasonable consideration in a practice setting where time in target range is less than 50%. A higher rate of utilization and a more aggressive stance toward subtherapeutic INR values could potentially enhance the effectiveness of an ACS.
Introduction and Background
Randomized trials have indicated that wellmonitored anticoagulation with warfarin could prevent more than half of the strokes related to atrial fibrillation [1] [2] [3] [4] [5] [6] [7] [8] . However, many of the patients who could benefit from this therapy either do not receive it or are not maintained within an optimal prothrombin time-international normalized ratio (INR) range [7] [8] [9] [10] . One strategy proposed for improving warfarin treatment has been an anticoagulation clinic service (ACS), which can potentially monitor the patient at regular intervals; maintain records on medications, comorbid conditions, and laboratory values; use a standard algorithm for setting dosage; and report regularly to the physician primarily responsible for the patient's care. The Managing Anticoagulation Services Trial (MAST) was launched in 1996 to assess the efficacy of an ACS within a managed care organization. Unlike most individual or group practices, these larger organizations have the patient population and the resources to support this alternative.
Patients, Methods, and Design
To be eligible for the study, patients had to be 65 years or older, have a diagnosis of atrial fibrillation as the primary reason for anticoagulation, and be enrolled in one of six managed care organizations which were selected as study sites. Patients were excluded if they had mechanical heart valves, atrial fibrillation due to reversible causes (e.g., thryrotoxicosis), or a life expectancy of less than 6 months.
At each managed care site, two geographically related groups of practices with approximately 200-250 patients ≥65 years who had atrial fibrillation were designated as practice clusters. We randomly assigned one practice cluster in each area to the intervention and the other to the control. Patients in the practice groups designated as intervention could
The author is grateful to Annette Jurgelski and Gregory Samsa for assistance in preparation of this manuscript, as well as for their central roles in the development and implementation of MAST. be referred to an ACS which was set up by the managed care organization for the trial. Patients in the usual care groups could not be referred to the ACS established for the trial, but no other constraints were placed on their care. Although the six sites had latitude in structuring their anticoagulation services, each had to fulfill three core functions: management of anticoagulation by a qualified midlevel provider, provision of educational services to patients, and outreach to support patient recruitment.
The timeline for the trial included a baseline period of 9 months before the anticoagulation service was initiated, a run-in period of 6-14 months depending on the time required to enroll patients, and a follow-up period of 9 months commencing immediately after the ACS attained a minimum enrollment. At the end of the follow-up period, data were obtained by abstracting the records of eligible patients in both clusters for the baseline and follow-up period. The primary outcome measure was quality of anticoagulation management, defined as the proportion of time that prothrombin timeinternational normalized ratio (INR) values were within their target ranges, i.e., proportion of patientdays for which the INR was between 2 and 3. Secondary outcome measures were time to follow-up of out-of-range values, incidence of thromboembolic events (stroke, deep venous thrombosis, pulmonary embolism or other visceral infarction) and major bleeding.
Results
Our primary hypothesis was that an ACS could function within a managed care organization and that its availability would increase the number of eligible patients receiving warfarin and improve the quality of their care. Five of the six sites participating in the trial were successful in establishing an ACS. The percentage of eligible providers who used the service ranged from 14% to 78%. In the intervention clusters, 363 (61%) of the 593 patients whose charts were abstracted were treated with warfarin and 173 (48%) of these were enrolled in the ACS sponsored by the managed care organization. In the control clusters, 317 (55%) of the 572 patients whose charts were abstracted were treated with warfarin (Figure 1) . A comparison of patients in both groups for whom data were available for both baseline and follow-up period showed similar changes in percentages of time in the target range (Figure 2) . For intervention clusters, 47.7% were in range at baseline and 55.6% were in range at followup. For control clusters, 49.1% were in range at baseline and 52.3% were in range at follow-up (intervention effect: 5%; 95% confidence level:-5% to 14%; P = 0.32). There was a non-significant trend towards earlier follow-up of high out-of-range INR re- sults for patients in the ACS cluster. We noted no statistical differences between clusters in rates of thromboembolism, hospitalization, and major bleeding. In both clusters, patients had slightly subtherapeutic INR values (1.5 to 1.99) about one fourth of the time.
